D. C. Quenelle, B. Lampert, D. J. Collins, T. L. Rice, G. R. Painter, E. R. Kern: Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. In: The Journal of Infectious Diseases. Band 202, Nummer 10, November 2010, S. 1492–1499, doi:10.1086/656717. PMID 20923374. PMC 2957530 (freier Volltext).
Irma M. Grossi, Scott A. Foster, Melicia R. Gainey, Robert Krile, John A. Dunn, Thomas M. Brundage, Jody M. Khouri: Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits. In: Antiviral Research. 2017, Band 143, S. 278–286 doi:10.1016/j.antiviral.2017.04.002.
A. E. Tollefson, J. F. Spencer, B. Ying, R. M. Buller, W. S. Wold, K. Toth: Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. In: Antiviral Research. Band 112, Dezember 2014, S. 38–46, doi:10.1016/j.antiviral.2014.10.005. PMID 25453340.
D. F. Smee, A. Dagley, B. Downs, J. Hagloch, E. B. Tarbet: Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice. In: Antimicrobial Agents and Chemotherapy. [elektronische Veröffentlichung vor dem Druck] November 2014, doi:10.1128/AAC.04289-14. PMID 25385098.
D. F. Florescu, M. A. Keck: Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. In: Expert review of anti-infective therapy. Band 12, Nummer 10, Oktober 2014, S. 1171–1178, doi:10.1586/14787210.2014.948847. PMID 25120093.
D. C. Quenelle, B. Lampert, D. J. Collins, T. L. Rice, G. R. Painter, E. R. Kern: Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. In: The Journal of Infectious Diseases. Band 202, Nummer 10, November 2010, S. 1492–1499, doi:10.1086/656717. PMID 20923374. PMC 2957530 (freier Volltext).
A. E. Tollefson, J. F. Spencer, B. Ying, R. M. Buller, W. S. Wold, K. Toth: Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. In: Antiviral Research. Band 112, Dezember 2014, S. 38–46, doi:10.1016/j.antiviral.2014.10.005. PMID 25453340.
D. F. Smee, A. Dagley, B. Downs, J. Hagloch, E. B. Tarbet: Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice. In: Antimicrobial Agents and Chemotherapy. [elektronische Veröffentlichung vor dem Druck] November 2014, doi:10.1128/AAC.04289-14. PMID 25385098.
D. F. Florescu, M. A. Keck: Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. In: Expert review of anti-infective therapy. Band 12, Nummer 10, Oktober 2014, S. 1171–1178, doi:10.1586/14787210.2014.948847. PMID 25120093.
